China Establishes Market-Price Database, Reshaping Global Pricing Signals
China’s new drug price database marks a subtle but important shift in price governance—separating how market prices are recorded from how reimbursement is negotiated. The change reshapes pricing signals in ways that matter for both domestic innovators and multinational firms.
China’s Biosimilar VBP: Emerging Rules, Pricing Dynamics, and What Early Signals Suggest
China’s VBP is shifting toward biosimilars, raising strategic questions for global manufacturers: Will the country cultivate an EU-style biosimilar market—and will VBP mirror generics or follow a modified path? This series interprets early policy signals to help companies prepare.
NHSA Consults on 2025 Dual-List Adjustment Work Plan for NRDL and Commercial Drug List
The Dual-List Adjustment Mechanism marks a pivotal shift in China’s reimbursement system, prompting key strategic questions for innovative drug makers.
The Future of Innovative Medicine Pricing and Reimbursement in China: Signals from the 2024 NRDL Negotiations
These developments call for a global pricing strategy rooted in China's evolving reimbursement infrastructure, breaking siloed thinking to balance short-term goals with long-term growth.
Inside Look: A Former NHSA Official's Take on Pricing Medical Innovations
These perspectives provide unique insights into what may contribute to NHSA's decision criteria in pricing medical innovations and allocating healthcare resources.
Advancements in China's BMI Payment Policies for High-Value Medical Consumables: How MedTech Should Prepare
These policies create a national framework for the pricing and reimbursement of high-value medical consumables under basic medical insurance schemes, necessitating proactive preparedness from MedTech firms.
Quantifying Innovation: Three Key Signals from NHSA's Draft on New Chemical Drug Launch Pricing
The standout enhancement in the current proposal is the addition of a self-assessment scale. This tool, designed to assign a score that quantifies innovation quality based on the company's self-assessment, plays a crucial role in determining the initial pricing of their drugs.
Pudong Drug Pricing Pilot
#1 Pudong reform pilot permits new drug launch pricing comparable to international markets.
On January 22nd, a joint announcement was
